[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The second PD-1 blocker, often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.\"","after":"\"Nivolumab was the second PD-1 blocker and is often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.\""}]},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/drugs.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"asOf"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]}]